Business Context and Reporting Period
This Form 8-K is filed by OncoCyte Corporation (trading symbol: OCX) on January 29, 2021. The report details a material event regarding the acquisition of Razor Genomics, Inc. ("Razor"), a transaction stemming from agreements dated September 4, 2019. OncoCyte holds rights to develop and market its lead diagnostic test, DetermaRx, through these agreements with Razor.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the specific transaction costs for the Razor acquisition:
- Total Consideration: $15 million
- Cash Component: $10 million payable to Encore Clinical, Inc. and Minority Shareholders.
- Stock Component: $5 million in OncoCyte common stock, valued based on a five-day average closing price on the NYSE American.
Material Changes
The principal shareholder of Razor notified OncoCyte that a milestone requiring the purchase of outstanding Razor common stock has been attained. Upon closing, OncoCyte will become the sole shareholder of Razor. This represents a material change in the company's asset base and ownership structure, though the filing notes the closing is subject to customary conditions.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook beyond the completion of the Razor acquisition. Management directs investors to the "Risk Factors" section of the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for factors that could cause actual results to differ from forward-looking statements. The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the satisfaction of customary closing conditions required to finalize the Razor acquisition.
- Confirm the exact number of OncoCyte shares to be issued based on the five-day average closing price calculation.
- Review the September 4, 2019 Purchase Agreement and Minority Purchase Agreements for specific terms regarding the DetermaRx diagnostic test rights.
- Assess the impact of the $10 million cash outlay on OncoCyte's current liquidity position.